je.st
news
Mayne shares fall on Doryx slump
2014-11-27 13:29:15| Biotech - Topix.net
Shares in Mayne Pharma Group have fallen sharply after the drug developer and manufacturer said it was facing headwinds with its franchise for the Doryx acne treatment in the United States. Sales of US Doryx rose 60 per cent to $US21 million in 2013/14 following the launch of a 200mg strength tablet.
Tags: fall
shares
slump
mayne
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||